ReviewJournal of nanobiotechnology2025
Ultrasound-driven atherosclerosis nanomedicine: from mechanical, cavitation, and sonodynamic therapies to bedside translation.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nanosonosensitizers in antibacterial sonodynamic therapy: mechanism exploration, activity enhancement strategies, and current status of antibacterial applications.Ultrasonics sonochemistry · 2026Article
- Effects of operating parameters on bubble collapse temperature and sonochemical product yields in dual‑frequency acoustic cavitation.Ultrasonics sonochemistry · 2026Article
- Ultrasound-Mediated Thrombolysis: From Mechanistic Insights to Advanced Nanoplatforms and Clinical Translation.Advanced healthcare materials · 2026Review
- Ultrasound-Activated Prodrugs for Precision Cancer Therapy: From Mechanical and Cavitation Effects to Advanced Sonochemical Activation.Chem & bio engineering · 2026Review
- Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Atherosclerosis (AS) is a leading cause of cardiovascular mortality worldwide, highlighting an urgent need for innovative, non-invasive therapies to address plaque instability and acute cardiovascular events. Ultrasound technology has emerged as a transformative platform, utilizing mechanical, cavitation, and sonodynamic effects to specifically target the pathological mechanisms of AS. This review systematically explores three key therapeutic strategies: first, ultrasound thermal and mechanical effects for direct plaque disruption and enhanced drug delivery; second, cavitation-mediated thrombolysis and modulation of the plaque microenvironment, and third, sonodynamic effects triggering reactive oxygen species (ROS)-induced apoptosis or autophagy. Furthermore, this review provides a comprehensive summary of the clinical progress of ultrasound-driven thrombolytic therapy and sonodynamic therapy for AS. Although ultrasound therapy for AS has achieved preclinical success with some advancing to clinical trials, challenges remain in balancing ultrasound parameters, reducing ROS toxicity, and ensuring the long-term biosafety of sonosensitizers. By discussing ultrasound therapeutic mechanisms, sonosensitizer design, and clinical applications, this review aims to provide valuable insights for the advancement of the nanomedicine field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.